ITonis

ITonis EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of ITonis (ITNS) as of Oct 25, 2026 is -172.99. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was -202.25 — a change of -14.47% (higher).

EV/EBITDA

-172.99

YoY

-14.47%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of ITonis is 2025 -172.99 . EV/EBITDA (Enterprise Value to EBITDA) of ITonis was 2024 -202.25 . It decreases by -14.47% higher compared to the previous year.

The ITonis EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-23.47 USD
Jan 1, 2019
-28.45 USD
Jan 1, 2020
-37.20 USD
Jan 1, 2021
-26.08 USD
Jan 1, 2022
-219.99 USD
Jan 1, 2023
-47.61 USD
Jan 1, 2024
-202.25 USD
Jan 1, 2025
-172.99 USD
The ITonis EV/EBITDA history
YEAREV/EBITDAYoY
-172.99-14.47%
-202.25+324.79%
-47.61-78.36%
-219.99+743.50%
-26.08-29.89%
-37.20+30.75%
-28.45+21.24%
-23.47-8.27%
-25.58+586.56%
-3.73+28.77%
-2.89+15.56%
-2.50—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ITonis Stock analysis

What does ITonis do? Itonis, Inc. generates revenue through the distribution of its homeopathic anti-nausea product Emesyl to the medical and pharmaceutical industry. The company markets Emesyl, an over-the-counter and prescription homeopathic preparation, primarily targeting the general public suffering from nausea. Sales occur via Amazon and the company's website Emesyl.com. The firm's subsidiaries, Itonis Holdings, Inc. and Paramount Discoveries, Inc., support its operations in the pharmaceutical sector. Emesyl is positioned as a solution for common ailments, with its availability on Amazon and Emesyl.com enabling direct consumer access. The company's focus on both over-the-counter and prescription products allows it to serve diverse customer segments within the healthcare market. Itonis Pharmaceuticals division handles the production and marketing of these homeopathic preparations. The business model relies on the sale of Emesyl through established retail channels and direct online sales, leveraging the brand's presence on Amazon and its dedicated website. This approach targets individuals seeking nausea relief without requiring a prescription, aligning with the product's over-the-counter status and broad market appeal. ITonis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ITonis stock

EV/EBITDA (Enterprise Value to EBITDA) of ITonis is -172.99 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of ITonis changed from -202.25 to -172.99, representing a -14.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) ITonis since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s ITonis with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ITonis

All Key Metrics — ITonis